Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ZAGG Roth Capital Maintains Neutral On Zagg Following 3Q14 Earnings Release http://www.smarteranalyst.com/2014/11/05/roth-capital-maintains-neutral-on-zagg-following-3q14-earnings-release/
$ZAGG Roth Capital Maintains Neutral On Zagg Following 3Q14 Earnings Release http://www.smarteranalyst.com/2014/11/05/roth-capital-maintains-neutral-on-zagg-following-3q14-earnings-release/
$BABA Cantor Analyst Maintains Bullish Stance On Alibaba As It Impresses With First Earnings Statement http://www.smarteranalyst.com/2014/11/05/cantor-analyst-maintains-bullish-stance-on-alibaba-as-it-impresses-with-first-earnings-statement/
$REGN Roth Capital Remains Positive On Regeneron Pharmaceuticals Following 3Q14 Results http://www.smarteranalyst.com/2014/11/05/roth-capital-remains-positive-on-regeneron-pharmaceuticals-following-3q14-results/
$REGN Roth Capital Remains Positive On Regeneron Pharmaceuticals Following 3Q14 Results http://www.smarteranalyst.com/2014/11/05/roth-capital-remains-positive-on-regeneron-pharmaceuticals-following-3q14-results/
$ACHN Maxim Maintains Buy On Achillion Pharmaceuticals Following 3Q14 Update http://www.smarteranalyst.com/2014/11/05/maxim-maintains-buy-on-achillion-pharmaceuticals-following-3q14-update/
$AEZS Maxim Raises Aeterna Zentaris Price Target Following 3Q14 Results http://www.smarteranalyst.com/2014/11/05/maxim-raises-aeterna-zentaris-price-target-following-3q14-results/
$AEZS Maxim Raises Aeterna Zentaris Price Target Following 3Q14 Results http://www.smarteranalyst.com/2014/11/05/maxim-raises-aeterna-zentaris-price-target-following-3q14-results/
$ACUR Acura Quarterly Update; Roth Capital Reiterates Buy http://www.smarteranalyst.com/2014/11/05/acura-quarterly-update-roth-capital-reiterates-buy/
$CLDX Celldex Remains A Premier Immunotherapy Player To Watch Going Into 2015, Says Roth Capital http://www.smarteranalyst.com/2014/11/05/celldex-remains-a-premier-immunotherapy-player-to-watch-going-into-2015-says-roth-capital/
$AVNR Deutsche Bank Initiates Buy On Avanir Pharmaceuticals; Sees 27% Upside For The Stock http://www.smarteranalyst.com/2014/11/04/deutsche-bank-initiates-buy-on-avanir-pharmaceuticals-sees-27-upside-for-the-stock/
$BABA Cantor Comments On Alibaba Following Earnings Release; Raises PT To $110 http://www.smarteranalyst.com/2014/11/04/cantor-comments-on-alibaba-following-earnings-release-raises-pt-to-110/
$BABA Cantor Comments On Alibaba Following Earnings Release; Raises PT To $110 http://www.smarteranalyst.com/2014/11/04/cantor-comments-on-alibaba-following-earnings-release-raises-pt-to-110/
$GALE Galena: We Continue To Believe The Company’s Fundamental Thesis Remains Strong, Says Roth Capital http://www.smarteranalyst.com/2014/11/04/galena-we-continue-to-believe-the-companys-fundamental-thesis-remains-strong-says-roth-capital/
$ICPT Oppenheimer Comments On Intercept As FLINT Manuscript Has Been Accepted For Publication In A Journal http://www.smarteranalyst.com/2014/11/04/oppenheimer-comments-on-intercept-as-flint-manuscript-has-been-accepted-for-publication-in-a-journal/
$ANIP Oppenheimer Raises ANI Pharmaceuticals Price Target Following Strong 3Q14 Results http://www.smarteranalyst.com/2014/11/04/oppenheimer-raises-ani-pharmaceuticals-price-target-following-strong-3q14-results/
$CLDX Oppenheimer Reiterates Outperform On Celldex Therapeutics, Sees 117% Upside http://www.smarteranalyst.com/2014/11/04/oppenheimer-reiterates-outperform-on-celldex-therapeutics-sees-117-upside/
$GALE Galena Quarterly Update; Oppenheimer Reiterates Perform http://www.smarteranalyst.com/2014/11/04/galena-quarterly-update-oppenheimer-reiterates-perform/
Oppenheimer Reiterates Perform On Shares Of Sprint Nextel http://www.smarteranalyst.com/2014/11/04/oppenheimer-reiterates-perform-on-shares-of-sprint-nextel/
$SRPT Roth Capital Comments On Sarepta Therapeutics Ahead Of 3Q14 Update http://www.smarteranalyst.com/2014/11/04/roth-capital-comments-on-sarepta-therapeutics-ahead-of-3q14-update/
$SRPT Roth Capital Comments On Sarepta Therapeutics Ahead Of 3Q14 Update http://www.smarteranalyst.com/2014/11/04/roth-capital-comments-on-sarepta-therapeutics-ahead-of-3q14-update/
$ANIP Roth Capital Raises ANI Pharmaceuticals Price Target Following 3Q14 Results http://www.smarteranalyst.com/2014/11/04/roth-capital-raises-ani-pharmaceuticals-price-target-following-3q14-results/
$MNKD MLV Reduced MannKind Price Target On A Detailed Review Of The Capital Structure http://www.smarteranalyst.com/2014/11/04/mlv-reduced-mannkind-price-target-on-a-detailed-review-of-the-capital-structure/
$GALE Maxim Maintains Buy On Galena Following 3Q14 Earnings And Clinical Progress Update http://www.smarteranalyst.com/2014/11/04/maxim-maintains-buy-on-galena-following-3q14-earnings-and-clinical-progress-update/
$MSFT Microsoft Shares Do Not Appear Cheap, Says Deutsche Bank http://www.smarteranalyst.com/2014/11/03/microsoft-shares-do-not-appear-cheap-says-deutsche-bank/
$GERN MLV Maintains Buy On Geron As Full Clinical Hold On Imetelstat Lifted http://www.smarteranalyst.com/2014/11/03/mlv-maintains-buy-on-geron-as-full-clinical-hold-on-imetelstat-lifted/
$GALT MLV Maintains Buy On Galectin Therapeutics; Sees 194% Upside For The Stock http://www.smarteranalyst.com/2014/11/03/mlv-maintains-buy-on-galectin-therapeutics-sees-194-upside-for-the-stock/
$CLNE MLV Maintains Hold On Clean Energy Fuels Following CFO Resignation http://www.smarteranalyst.com/2014/11/03/mlv-maintains-hold-on-clean-energy-fuels-following-cfo-resignation/
$CLNE MLV Maintains Hold On Clean Energy Fuels Following CFO Resignation http://www.smarteranalyst.com/2014/11/03/mlv-maintains-hold-on-clean-energy-fuels-following-cfo-resignation/
$KORS Michael Kors: 2Q Could See Upside, But Stock Needs Reset Catalyst, Says Deutsche Bank http://www.smarteranalyst.com/2014/11/03/michael-kors-2q-could-see-upside-but-stock-needs-reset-catalyst-says-deutsche-bank/
$ABX Deutsche Bank Questioned Barrick's Ability To Deleverage Its Balance Sheet http://www.smarteranalyst.com/2014/11/03/deutsche-bank-questioned-barricks-ability-to-deleverage-its-balance-sheet/
$XOM Oppenheimer Maintains Pefrom On Exxon Mobil Following 3Q14 Earnings http://www.smarteranalyst.com/2014/11/03/oppenheimer-maintains-pefrom-on-exxon-mobil-following-3q14-earnings/
$PCLN Cantor Sets Expectations On Priceline.com Into 3Q14 Results http://www.smarteranalyst.com/2014/11/03/cantor-sets-expectations-on-priceline-com-into-3q14-results/
$PCLN Cantor Sets Expectations On Priceline.com Into 3Q14 Results http://www.smarteranalyst.com/2014/11/03/cantor-sets-expectations-on-priceline-com-into-3q14-results/
$JAZZ Cantor Raises Jazz Pharmaceuticals Price Target On Xyrem Scenario Analysis http://www.smarteranalyst.com/2014/11/03/cantor-raises-jazz-pharmaceuticals-price-target-on-xyrem-scenario-analysis/
$AOL Steady Improvement Likely To Persist In 3Q Results, Says Cantor http://www.smarteranalyst.com/2014/11/03/steady-improvement-likely-to-persist-in-3q-results-says-cantor/
$RPRX Brean Capital Maintains Buy On Repros Therapeutics Following Analyst Day http://www.smarteranalyst.com/2014/11/03/brean-capital-maintains-buy-on-repros-therapeutics-following-analyst-day/
$RPRX Brean Capital Maintains Buy On Repros Therapeutics Following Analyst Day http://www.smarteranalyst.com/2014/11/03/brean-capital-maintains-buy-on-repros-therapeutics-following-analyst-day/
$OMER Omeros: We See Potential Upside in Transitional Pass-Through Reimbursement of Omidria, Says MLV http://www.smarteranalyst.com/2014/10/31/omeros-we-see-potential-upside-in-transitional-pass-through-reimbursement-of-omidria-says-mlv/
$AGEN Maxim Reiterates Buy On Agenus Following 3Q14 Update; Sees 183% Upside For The Stock http://www.smarteranalyst.com/2014/10/31/maxim-group-reiterates-buy-on-agenus-following-3q14-update-sees-183-upside-for-the-stock/